BIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Bio-Rad Laboratories Inc (BIO) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is experiencing significant post-market declines (-14.16%), weak technical indicators, and disappointing financial performance. Additionally, there are no strong positive catalysts or trading signals to suggest a recovery in the near term.
The MACD histogram is negative and expanding (-0.537), indicating bearish momentum. RSI is at 36.238, suggesting the stock is nearing oversold territory but not yet a buy signal. Moving averages are converging, showing no clear trend. Key support levels are at $286.211 and $278.954, with resistance at $297.957 and $309.704. The stock is trading significantly below its pivot point ($297.957), reflecting bearish sentiment.
Hedge funds have significantly increased their buying activity (up 333305.80% over the last quarter), which could indicate institutional confidence in the stock's long-term potential.
Core business performance remains underwhelming, limiting long-term growth potential. Technical indicators and stock trend analysis suggest further declines (-6.83% in the next week, -6.3% in the next month).
In Q4 2025, revenue increased by 3.9% YoY to $693 million, beating expectations by $5.49 million. However, gross margin declined, and non-GAAP EPS of $2.51 missed estimates by $0.19. For 2025/Q3, revenue grew marginally by 0.50% YoY, but net income dropped by -152.34% YoY to -$341.9 million, and EPS fell by -154.41% YoY to -$12.7. Gross margin also declined by -4.16% YoY to 52.5%. These results indicate significant pressure on profitability and weak overall financial health.
Analyst ratings and price target changes are not provided. However, the company's recent earnings miss and underwhelming core business performance suggest a bearish outlook among analysts.
